

TEST REPORT



E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #62755

Testing ordered > 28 MAR '25

Sample received > 10 APR '25

Client Qing

Sample AOD9604

Manufacturer www.qinglish.com

Batch 5AD/2025-04

Sample description >

Pictures not included.

Tests requested >

Assessment of a peptide vial or vials.

Results >



AOD-9604	4.42 mg
Purity	99.630%

Comments >

Analysis conducted > 16 APR 2025

Signature >

A handwritten signature in black ink, appearing to be 'JANOSHNIK'.

Verify this test at www.janoshik.com/verify/ with the following unique key

AHYRCEBSDEJ2

AOD-9604 5mg Technical Data Sheet

OPTIMAL BIO LABS — TECHNICAL DATA SPECIFICATION SHEET

[✓] ORIGINAL COA / TEST REPORT ATTACHED — PAGE 1

[✓] QUALITY ASSURANCE PROGRAM — PAGE 3

CORE TECHNICAL DATA MATRIX

Product Nomenclature	AOD-9604 Reference Standard
Molecular Classification	Carboxy -Terminus Lipolytic Fragment Sequence
Chemical Profile Alias	Synthetic Lipolytic Core Chain Derivative
CAS Registry Number	221231-10-3
Molecular Formula	C78H123N23O23S2
Molar Mass	1815.1 g/mol

MATERIAL PARAMETERS & SPECIFICATIONS

Form	Lyophilized freeze-dried powder matrix
Baseline Quality Standard	Verified ≥98.0% via high-performance liquid chromatography (HPLC).
Lot Verification	Sequence matrix matched via analytical mass spectrometry (MS) profile.
Storage Environment	Maintain sealed containment at -20°C, fully insulated from ambient moisture and light. Follow lot-specific instructions when supplied.
Target Application	Intended solely for parallel laboratory research mapping multi-variable hormone axis models.
Analytical Documentation	Results apply only to the sample and lot identified in the attached report.

Target application: For in-vitro laboratory research only. Not for human or veterinary use.

Chemical reference: PubChem compound record. Product specification: Optimal Bio Labs product listing.

Quality Assurance Protocol & Sourcing Transparency

1. Specification Baseline & Quality Threshold

Optimal Bio Labs operates under a standardized Quality Assurance Program. Every synthesized lot is managed against a 99%+ batch target, with a strict baseline purity threshold set at 98.0%. For product variations where a pre-linked independent analysis is unavailable, our internal quality validation framework remains fully active to ensure structural and analytical compliance before inventory release.

2. Sourcing Transparency & Verification Channels

We maintain direct, long-term relationships with a highly selective network of primary synthesis manufacturers. To protect proprietary trade channels and supply logistics, we do not utilize third-party brokers or downstream distributors.

Analytical data and reference documentation are compiled using multi-layered validation sources, which may include direct facility mapping, industry-standard third-party auditing via Fennrick, or independent validation by domestic testing laboratories. Where external reports are generated, they are often routed through the primary source (c/o Optimal Bio Labs) to ensure unaltered documentation for that specific batch variation. Qualifying independent records can be cross-referenced directly through the testing facility's verification systems.

3. Specification Discrepancy & Account Adjustments

We stand behind our strict quality baseline. In the event that a sealed, unopened reference unit from a qualifying lot is submitted to Fennrick for independent verification and returns an objective analytical purity reading below our 98.0% baseline threshold, the following standardized adjustment protocols apply:

- **Material Valuation Credit:** A balance reallocation will be applied to the account covering the baseline cost of the verified lot variation.
- **Logistical Cost Offset:** Account adjustments include credit allocations for standard logistics costs associated with the independent verification process and sample delivery, subject to our published terms and conditions.

Authenticity Through Verifiable Analysis.